Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.41 |
| ▸ | PARP11 | Q9NR21 | 4/20 | 0.41 |
| ▸ | PARP1 | P09874 | 4/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | PRCP | P42785 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL23045213 | 0.98 | PARP10 (0.40) | PARP10PARP11PARP1S1PR1S1PR3 | |
| Hydrochloric Acid SCHEMBL29974603 | 0.98 | PARP10 (0.40) | PARP10PARP11PARP1S1PR1S1PR3 | |
| SCHEMBL15312190 | 0.81 | PARP10 (0.47) | PARP10PARP11PARP1S1PR1S1PR3 | |
| SCHEMBL31121854 | 0.81 | PARP10 (0.47) | PARP10PARP11PARP1S1PR1S1PR3 | |
| SCHEMBL15311463 | 0.81 | PARP10 (0.52) | PARP10PARP11PARP1 | |
| SCHEMBL20539302 | 0.78 | NOTUM (0.47) | PARP10PARP11PARP1S1PR1S1PR3 | |
| SCHEMBL30916119 | 0.78 | NOTUM (0.47) | PARP10PARP11PARP1S1PR1S1PR3 | |
| SCHEMBL4718535 | 0.78 | PARP10 (0.64) | PARP10PARP11PARP1S1PR1S1PR3 | |
| SCHEMBL29648250 | 0.78 | PARP10 (0.64) | PARP10PARP11PARP1S1PR1S1PR3 | |
| SCHEMBL30421356 | 0.74 | PARP10 (0.44) | PARP10PARP11PARP1S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230109839-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | Sumitomo Pharma Co., Ltd. (JP) | 2023-04-13 | — | — | US | disclosed |
| WO-2021039961-A1 | RING-FUSED PYRAZOLE DERIVATIVE | 大日本住友製薬株式会社 | 2021-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230109839-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | MAPT, PSEN1, PSEN2 | PARP10 2325/4885PARP11 2875/4885PARP1 2941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.